uniQure — The Gene Therapy Railroad - $QURE

From the devastating commercial collapse of the world’s first approved gene therapy to a breathtaking 70% stock surge sparked by a sudden FDA reversal, the story of uniQure N.V. (NASDAQ: QURE) is arguably the most improbable survival saga in modern biotech history. Once left for dead after its million-dollar treatment Glybera sold a grand total of one unit, the Dutch-American pioneer didn't retreat; instead, it completely rewrote its playbook, transitioning from bespoke, ultra-orphan drug development to building a modular, multi-billion-dollar "gene therapy railroad." By leveraging brilliant financial engineering—including a blockbuster Hemophilia B licensing deal and asset-light manufacturing restructurings—uniQure has kept itself well-capitalized to chase the holy grail of genetic medicine: the first-ever disease-modifying treatment to slow Huntington's disease. Step inside this masterclass of strategic resilience, capital allocation, and regulatory chess to discover how a company once crushed by its own pioneering science is now standing on the absolute precipice of medical history.---Subscribe to our newsletter on LinkedIn https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7408775804387491842Follow us on X @emportop---Transcript - https://empor.top/us/QUREI. Introduction & Episode RoadmapII. The Pioneers of Gene Therapy: Amsterdam Molecular TherapeuticsIII. Glybera: The World's First Approved Gene Therapy and Its Commercial DemiseIV. The Hemophilia B Miracle & The CSL Behring PartnershipV. Capital Allocation & Surgical M&A: Benchmarking the Corlieve AcquisitionVI. The "Hidden" Businesses Within uniQure: Platforms & ManufacturingVII. Current Management: Matthew Kapusta's Tenure, Shareholding, & IncentivesVIII. The Huntington's Disease Holy Grail: The June 17, 2026 Regulatory BreakthroughIX. Playbook: Business & Investing LessonsX. Frameworks: Hamilton's 7 Powers & Porter's Five ForcesXI. Epilogue: The Horizon of Gene TherapyReferences